These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right. — Barrons.com

By Mackenzie TatananniFrom speculation over mergers and acquisitions to the hype surrounding clinical readouts, it seems biotechnology stocks are all the rage this year.The iShares Biotechnology exchange-traded fund has risen nearly 23% this year against a 14% gain in the benchmark S&P 500 index. T…